sorafenib has been researched along with 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2-chloro-N-(5-methyl-3-isoxazolyl)acetamide) | Trials (2-chloro-N-(5-methyl-3-isoxazolyl)acetamide) | Recent Studies (post-2010) (2-chloro-N-(5-methyl-3-isoxazolyl)acetamide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 6 | 0 | 1 |
| Protein | Taxonomy | sorafenib (IC50) | 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Ashmawy, MB; El-Gohary, NS; Shehata, IA; Warda, ET | 1 |
1 other study(ies) available for sorafenib and 2-chloro-N-(5-methyl-3-isoxazolyl)acetamide
| Article | Year |
|---|---|
New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Topics: Apoptosis; Binding Sites; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Isoxazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2020 |